Mutation of RNA polymerase β subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4188-4195

  Matsuo, Miki ^a   Hishinuma, Tomomi ^a   Katayama, Yuki ^a   Cui, Longzhu ^a   Kapi, Maria ^b   Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b Lab Vaos   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; VANCOMYCIN;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GENE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM MUTANT; CONTROLLED STUDY; GENETIC CODE; MICROBIAL POPULATION DYNAMICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DNA-DIRECTED RNA POLYMERASES; MICROBIAL SENSITIVITY TESTS; MUTATION; RIFAMPIN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 80051806726     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00398-11     Document Type: Article

References (48)

1. Bae, T, and O. Schneewind. 2006. Allelic replacement in Staphylococcus aureus with inducible counter-selection. Plasmid 55:58-63. (Pubitemid 41796953)
2. Bischoff, M, and B. Berger-Bachi. 2001. Teicoplanin stress-selected mutations increasing sigma(B) activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 45:1714-1720. (Pubitemid 32466339)
3. Campbell, E A, et al. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912. (Pubitemid 32289282)
4. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed., vol. 29, no. 2. Approved standard M07-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Cui, L., et al. 2006. Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:428-438. (Pubitemid 43190949)
6. Cui, L., E. Tominaga, H M Neoh, and K. Hiramatsu. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. (Pubitemid 43327815)
7. Cui, L., H M Neoh, M. Shoji, and K. Hiramatsu. 2009. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin- intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 53:1231-1234.
8. Cui, L., J Q Lian, H M Neoh, E. Reyes, and K. Hiramatsu. 2005. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3404-3413. (Pubitemid 41060589)
9. Cui, L., et al. 2010. An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 54:5222-5233.
10. Cui, L., et al. 2003. Cell Wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J. Clin. Microbiol. 41:5-14. (Pubitemid 36098547)
11. Daum, R S, S. Gupta, R. Sabbagh, and W M Milewski. 1992. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: Isolation and purification of a constitutively produced protein associated with decreased susceptibility. J. Infect. Dis. 166:1066-1072.
12. Eymann, C., G. Homuth, C. Scharf, and M. Hecker. 2002. Bacillus subtilis functional genomics: Global characterization of the stringent response by proteome and transcriptome analysis. J. Bacteriol. 184:2500-2520. (Pubitemid 34311144)
13. Finan, J E, G L Archer, M J Pucci, and M W Climo. 2001. Role of penicillin-binding protein 4 in expression of vancomycin resistance among clinical isolates of oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 45:3070-3075. (Pubitemid 32988830)
14. Gardete, S., S W Wu, S. Gill, and A. Tomasz. 2006. Role of VraSR in antibiotic resistance and antibiotic-induced stress response in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:3424-3434. (Pubitemid 44527519)
15. Hanaki, H., et al. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42:199-209. (Pubitemid 28393588)
16. Herbert, S., et al. 2007. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. PLoS Pathog. 3:e102.
17. Hiramatsu, K. 1998. Vancomycin resistance in staphylococci. Drug Resist. Updat. 1:135-150.
18. Hiramatsu, K. 2001. Vancomycin-resistant Staphylococcus aureus: A new model of antibiotic resistance. Lancet Infect. Dis. 1:147-155. (Pubitemid 33586048)
19. Hiramatsu, K, and H. Hanaki. 1998. Glycopeptide resistance in staphylococci. Curr. Opin. Infect. Dis. 11:653-658. (Pubitemid 29020872)
20. Hiramatsu, K., et al. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136. (Pubitemid 27341646)
21. Hiramatsu, K., et al. 2002. New trends in Staphylococcus aureus infections: Glycopeptide resistance in hospital and methicillin resistance in the community. Curr. Opin. Infect. Dis. 15:407-413. (Pubitemid 34816430)
22. Hiramatsu, K., et al. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673. (Pubitemid 28036828)
23. Howden, B P, et al. 2008. Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus. Antimicrob. Agents Chemother. 52:3755-3762.
24. Jansen, A., et al. 2007. Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int. J. Med. Microbiol. 297:205-215. (Pubitemid 46830043)
25. Katayama, Y., H. Murakami-Kuroda, L. Cui, and K. Hiramatsu. 2009. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob. Agents Chemother. 53:3190-3196.
26. Kondo, N., K. Kuwahara-Arai, H. Kuroda-Murakami, E. Tateda-Suzuki, and K. Hiramatsu. 2001. Eagle-type methicillin resistance: New phenotype of high methicillin resistance under mec regulator gene control. Antimicrob. Agents Chemother. 45:815-824. (Pubitemid 32182032)
27. Kraus, D., et al. 2008. The GraRS regulatory system controls Staphylococcus aureus susceptibility to antimicrobial host defenses. BMC Microbiol. 8:85.
28. Kuroda, M., et al. 2003. Two-component system VraSR positively modulates the regulation of cell-wall biosynthesis pathway in Staphylococcus aureus. Mol. Microbiol. 49:807-821. (Pubitemid 36918698)
29. Kuroda, M., K. Kuwahara-Arai, and K. Hiramatsu. 2000. Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method. Biochem. Biophys. Res. Commun. 269:485-490. (Pubitemid 30440327)
30. Li, M., et al. 2007. The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol. Microbiol. 66:1136-1147. (Pubitemid 350115022)
31. McCallum, N. et al. 2006. In vivo survival of teicoplanin-resistant Staphylococcus aureus and fitness cost of teicoplanin resistance. Antimicrob. Agents Chemother. 50:2352-2360. (Pubitemid 43993172)
32. Meehl, M., S. Herbert, F. Gotz, and A. Cheung. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2679-2689. (Pubitemid 47206200)
33. Mwangi, M M, et al. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 104:9451-9456. (Pubitemid 47185800)
34. Neoh, H M, et al. 2008. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 52:45-53.
35. Nishi, H., H. Komatsuzawa, T. Fujiwara, N. McCallum, and M. Sugai. 2004. Reduced content of lysyl-phosphatidylglycerol in the cytoplasmic membrane affects susceptibility to moenomycin, as well as vancomycin, gentamicin, and antimicrobial peptides, in Staphylococcus aureus. Antimicrob. Agents Chemother. 48:4800-4807. (Pubitemid 39577687)
36. Peschel, A., et al. 2001. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J. Exp. Med. 193:1067-1076. (Pubitemid 32436200)
37. Pfeltz, R F, et al. 2000. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob. Agents Chemother. 44:294-303. (Pubitemid 30060722)
38. Renzoni, A., et al. 2009. Identification by genomic and genetic analysis of two new genes playing a key role in intermediate glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 53:903-911.
39. Ruzin, A., et al. 2003. Inactivation of mprF affects vancomycin susceptibility in Staphylococcus aureus. Biochim. Biophys. Acta 1621:117-121. (Pubitemid 36515093)
40. Sakoulas, G., et al. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502. (Pubitemid 34415333)
41. Sakoulas, G., et al. 2005. Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob. Agents Chemother. 49:2687-2692. (Pubitemid 40917579)
42. Schulthess, B., et al. 2009. Functional characterization of the sigmaB-dependent yabJ-spoVG operon in Staphylococcus aureus: Role in methicillin and glycopeptide resistance. Antimicrob. Agents Chemother. 53:1832-1839.
43. Seidl, K., et al. 2006. Staphylococcus aureus CcpA affects virulence determinant production and antibiotic resistance. Antimicrob. Agents Chemother. 50:1183-1194.
44. Trotonda, M P, Y Q Xiong, G. Memmi, A S Bayer, and A L Cheung. 2009. Role of mgrA and sarA in methicillin-resistant Staphylococcus aureus autolysis and resistance to cell wall-active antibiotics. J. Infect. Dis. 199:209-218.
45. Watanabe, Y., H M Neoh, L. Cui, and K. Hiramatsu. 2008. Improved antimicrobial activity of linezolid against vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 52:4207-4208.
46. Watanabe, Y., L. Cui, Y. Katayama, K. Kozue, and K. Hiramatsu. 2011. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J. Clin. Microbiol. 49:2680-2684.
47. Wichelhaus, T A, V. Schafer, V. Brade, and B. Boddinghaus. 1999. Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2813-2816. (Pubitemid 29519574)
48. Zhou, Y N, and D J Jin. 1998. The rpoB mutants destabilizing initiation complexes at stringently controlled promoters behave like "stringent" RNA polymerases in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 95:2908-2913. (Pubitemid 128617610)